Aneal Tenjarla

Aneal Tenjarla, an associate portfolio manager at Sofinnova BioEquities, discusses Dexcom's groundbreaking continuous glucose monitors that have transformed diabetes management. They delve into the significant growth opportunities in the diabetes market, which faces rising treatment costs. Aneal shares insights on Dexcom's competitive edge over rivals like Abbott, exploring innovative strategies and the potential for technological partnerships. The conversation also touches on the evolving landscape of diabetes care and how customer acquisition dynamics are changing.